Neluxicapone Explained

Class:	Catechol O-methyltransferase inhibitor
Cas Number:	1498323-18-4
Pubchem:	90015465
Chemspiderid:	68007328
Unii:	ZO0K3RUH9L
Iupac Name:	4,5-dihydroxy-2-[(4-methylphenyl)methyl]benzene-1,3-dicarbonitrile
C:	16
H:	12
N:	2
O:	2
Smiles:	CC1=CC=C(C=C1)CC2=C(C(=C(C=C2C#N)O)O)C#N
Stdinchi:	1S/C16H12N2O2/c1-10-2-4-11(5-3-10)6-13-12(8-17)7-15(19)16(20)14(13)9-18/h2-5,7,19-20H,6H2,1H3
Stdinchikey:	GILLLKMLIBNDKV-UHFFFAOYSA-N

Neluxicapone is a catechol O-methyltransferase (COMT) inhibitor which has not been marketed as of 2024.^[1] ^[2] ^[3] The drug is a nitrocatechol and is structurally related to other catechol COMT inhibitors like entacapone, tolcapone, and nebicapone.^[4] COMT inhibitors are used in conjunction with levodopa in the treatment of Parkinson's disease. Neluxicapone was first described in the literature by 2018. Its was designated by the World Health Organization (WHO) in 2019.

Notes and References

Book: World Health Organization . 2018 . The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2018 (StemBook2018) . No. WHO/EMP/RHT/TSN/2018.1 . -capone catechol-O-methyltransferase (COMT) inhibitors. entacapone (65), nebicapone (96), neluxicapone (119), nitecapone (62), opicapone (103), tolcapone (66).
((World Health Organization)) . 2019 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81 . WHO Drug Information . 33 . 1 . 43–133 .
Web site: Neluxicapone . PubChem . U.S. National Library of Medicine . 8 October 2024.
Haasio K . Toxicology and safety of COMT inhibitors . International Review of Neurobiology . 95 . 163–189 . 2010 . 21095462 . 10.1016/B978-0-12-381326-8.00007-7 . 978-0-12-381326-8 .